Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.77 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.77 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.77 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefaloram SCHEMBL11057775 | 1.00 | TDP1 (1.00) | TDP1CTDSP1MAPTNR1I2HPGD | |
| Cefaloram SCHEMBL11057780 | 1.00 | TDP1 (1.00) | TDP1CTDSP1MAPTNR1I2HPGD | |
| Cefaloram SCHEMBL27274373 | 1.00 | TDP1 (1.00) | TDP1CTDSP1MAPTNR1I2HPGD | |
| Cefaloram SCHEMBL612836 | 1.00 | TDP1 (1.00) | TDP1CTDSP1MAPTNR1I2HPGD | |
| Cefaloram SCHEMBL10428695 | 1.00 | TDP1 (1.00) | TDP1CTDSP1MAPTNR1I2HPGD | |
| Cefaloram SCHEMBL8722133 | 0.99 | TDP1 (0.98) | TDP1CTDSP1MAPTNR1I2HPGD | |
| Cefaloram SCHEMBL1133618 | 0.95 | TDP1 (0.90) | TDP1CTDSP1MAPTNR1I2HPGD | |
| SCHEMBL22015085 | 0.94 | TDP1 (0.89) | TDP1CTDSP1MAPTNR1I2HPGD | |
| SCHEMBL11566566 | 0.93 | TDP1 (0.87) | TDP1CTDSP1MAPTNR1I2HPGD | |
| SCHEMBL11566449 | 0.92 | TDP1 (0.86) | TDP1CTDSP1MAPTNR1I2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251417-B2 | Antimicrobial compounds from the genus Delftia | MINISTRY OF HEALTH, STATE OF ISRAEL (IL) | 2025-03-18 | — | — | US | claimed |
| US-20230398194-A1 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE | THERIVA BIOLOGICS INC (US) | 2023-12-14 | — | — | US | claimed |
| US-20220348645-A1 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-03 | — | — | US | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2021159176-A1 | ANTIMICROBIAL COMPOUNDS | THE UNIVERSITY OF WOLLONGONG (AU) | 2021-08-19 | — | — | WO | claimed |
| WO-2021067628-A2 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20200370098-A1 | Compositions and Methods for Identifying Secretory Antibody-Bound Microbes | HATTERAS VENTURE PARTNERS V, LP | 2020-11-26 | — | — | US | claimed |
| WO-2020223259-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | ILLUMINA, INC. (US) | 2020-11-05 | — | — | WO | claimed |
| CN-109568323-A | Bactericidal composition and application thereof | 四环医药控股集团有限公司 | 2019-04-05 | — | — | CN | claimed |
| US-20190083599-A1 | Compositions and Methods for Treating an Inflammatory Disease or Disorder | HATTERAS VENTURE PARTNERS V, LP | 2019-03-21 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | claimed |
| WO-1990006928-A1 | 6-(1-CARBAMOYL-1-HYDROXYMETHYL)PENICILLANIC ACID DERIVATIVES | BARTH WAYNE E (US) | 1990-06-28 | — | — | WO | claimed |
| US-4797394-A | 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1989-01-10 | — | — | US | claimed |
| EP-0084925-B1 | 6-AMINOALKYLPENICILLANIC ACID 1,1-DIOXIDES AND DERIVATIVES AS BETA-LACTAMASE INHIBITORS | PFIZER INC. (US) | 1986-04-09 | — | — | EP | claimed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | claimed |
| US-4452796-A | ANTIBIOTICS | PFIZER INC. (US) | 1984-06-05 | — | — | US | claimed |
| US-4427678-A | 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1984-01-24 | — | — | US | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12251417-B2 | Antimicrobial compounds from the genus Delftia | TUFM, DPM1, MGAM | TDP1 1925/4885CTDSP1 3334/4885MAPT 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.